SG11201605417QA - Heterocyclic compounds - Google Patents
Heterocyclic compoundsInfo
- Publication number
- SG11201605417QA SG11201605417QA SG11201605417QA SG11201605417QA SG11201605417QA SG 11201605417Q A SG11201605417Q A SG 11201605417QA SG 11201605417Q A SG11201605417Q A SG 11201605417QA SG 11201605417Q A SG11201605417Q A SG 11201605417QA SG 11201605417Q A SG11201605417Q A SG 11201605417QA
- Authority
- SG
- Singapore
- Prior art keywords
- heterocyclic compounds
- heterocyclic
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Otolaryngology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN362MU2014 | 2014-02-03 | ||
| IN2271MU2014 | 2014-07-11 | ||
| PCT/IN2015/000063 WO2015132799A2 (fr) | 2014-02-03 | 2015-02-02 | Nouveaux composés hétérocycliques |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201605417QA true SG11201605417QA (en) | 2016-08-30 |
Family
ID=53181312
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201605417QA SG11201605417QA (en) | 2014-02-03 | 2015-02-02 | Heterocyclic compounds |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US9840509B2 (fr) |
| EP (1) | EP3102579B1 (fr) |
| JP (1) | JP6162904B2 (fr) |
| CN (1) | CN105916859A (fr) |
| AP (1) | AP2016009297A0 (fr) |
| AU (1) | AU2015225745B2 (fr) |
| BR (1) | BR112016016844A2 (fr) |
| CA (1) | CA2934989C (fr) |
| EA (1) | EA201691302A1 (fr) |
| HK (1) | HK1223100A1 (fr) |
| IL (1) | IL246564A (fr) |
| MX (1) | MX2016009403A (fr) |
| NZ (1) | NZ721617A (fr) |
| PH (1) | PH12016501440A1 (fr) |
| SG (1) | SG11201605417QA (fr) |
| TW (1) | TWI542588B (fr) |
| WO (1) | WO2015132799A2 (fr) |
Families Citing this family (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3181567T (pt) | 2012-09-10 | 2019-06-24 | Principia Biopharma Inc | Compostos de pirazolopirimidina como inibidores de cinase |
| UY35464A (es) | 2013-03-15 | 2014-10-31 | Araxes Pharma Llc | Inhibidores covalentes de kras g12c. |
| JO3805B1 (ar) | 2013-10-10 | 2021-01-31 | Araxes Pharma Llc | مثبطات كراس جي12سي |
| KR20220027271A (ko) | 2014-02-21 | 2022-03-07 | 프린시피아 바이오파마, 인코퍼레이티드 | Btk 억제제의 염 및 고체 형태 |
| JO3556B1 (ar) | 2014-09-18 | 2020-07-05 | Araxes Pharma Llc | علاجات مدمجة لمعالجة السرطان |
| ES2843323T3 (es) | 2014-12-18 | 2021-07-16 | Principia Biopharma Inc | Tratamiento de pénfigo |
| WO2016106628A1 (fr) * | 2014-12-31 | 2016-07-07 | Merck Sharp & Dohme Corp. | Inhibiteurs de btk |
| CN107849022A (zh) | 2015-04-10 | 2018-03-27 | 亚瑞克西斯制药公司 | 取代的喹唑啉化合物和其使用方法 |
| WO2016168540A1 (fr) | 2015-04-15 | 2016-10-20 | Araxes Pharma Llc | Inhibiteurs tricycliques condensés de kras et procédés pour les utiliser |
| TW201718572A (zh) | 2015-06-24 | 2017-06-01 | 普林斯匹亞生物製藥公司 | 酪胺酸激酶抑制劑 |
| US10144724B2 (en) | 2015-07-22 | 2018-12-04 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use thereof |
| WO2017035366A1 (fr) | 2015-08-26 | 2017-03-02 | Incyte Corporation | Dérivés de type pyrrolo-pyrimidine utilisés comme inhibiteurs des tam |
| WO2017058768A1 (fr) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibiteurs de protéines kras portant la mutation g12c |
| US10858343B2 (en) | 2015-09-28 | 2020-12-08 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
| WO2017058915A1 (fr) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibiteurs de protéines mutantes kras g12c |
| EP3356339A1 (fr) | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibiteurs de protéines mutantes kras g12c |
| EP3356354A1 (fr) | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibiteurs de protéines kras portant la mutation g12c |
| US10875842B2 (en) | 2015-09-28 | 2020-12-29 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
| US10882847B2 (en) | 2015-09-28 | 2021-01-05 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
| AU2016355433C1 (en) | 2015-11-16 | 2021-12-16 | Araxes Pharma Llc | 2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof |
| CN108395446B (zh) | 2015-12-30 | 2020-02-28 | 南京中硼联康医疗科技有限公司 | 和β淀粉样蛋白特异性结合的化合物的制备方法 |
| TWI828027B (zh) * | 2016-03-28 | 2024-01-01 | 美商英塞特公司 | 作為tam抑制劑之吡咯并三嗪化合物 |
| CN107513068A (zh) * | 2016-06-16 | 2017-12-26 | 中国科学院上海药物研究所 | 一种具有fgfr抑制活性的新型化合物及其制备和应用 |
| AU2017290354C1 (en) | 2016-06-29 | 2023-07-06 | Principia Biopharma Inc. | Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile |
| KR102327917B1 (ko) * | 2016-07-07 | 2021-11-17 | 주식회사 대웅제약 | 신규한 4-아미노피라졸로[3,4-d]피리미디닐아자바이사이클로 유도체 및 이를 포함하는 약학 조성물 |
| US10646488B2 (en) | 2016-07-13 | 2020-05-12 | Araxes Pharma Llc | Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof |
| US10280172B2 (en) | 2016-09-29 | 2019-05-07 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
| US10377743B2 (en) | 2016-10-07 | 2019-08-13 | Araxes Pharma Llc | Inhibitors of RAS and methods of use thereof |
| JOP20190113A1 (ar) * | 2016-11-18 | 2019-05-15 | Biocad Joint Stock Co | مثبطات بروتون تيروزين كيناز |
| CN106883235B (zh) * | 2016-12-29 | 2019-04-30 | 天津国际生物医药联合研究院 | 恶二唑类化合物的制备和应用 |
| CN106588937B (zh) | 2017-01-16 | 2018-09-21 | 东莞市真兴贝特医药技术有限公司 | 咪唑并吡嗪类化合物及其制备方法和应用 |
| CN106831787B (zh) * | 2017-01-20 | 2018-10-23 | 成都倍特药业有限公司 | 用作布鲁顿酪氨酸激酶抑制剂的化合物及其制备方法和应用 |
| EP3573954A1 (fr) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | Composés benzohétéroaromatiques bicycliques fusionnés et leurs procédés d'utilisation |
| EP3573971A1 (fr) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | Dérivés de 1-(3-(6-(3-hydroxynaphtalen-1-yl)benzofuran-2-yl)azétidin-1yl)prop-2-en-1-one et composés similaires utilisés en tant que modulateurs de kras g12c pour le traitement du cancer |
| EP3573970A1 (fr) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | Dérivés de 1-(6-(3-hydroxynaphtalen-1-yl)quinazolin-2-yl)azétidin-1-yl)prop-2-en-1-one et composés similaires utilisés en tant qu'inhibiteurs de kras g12c pour le traitement du cancer |
| EP3573967A1 (fr) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | Composés hétéro-hétéro-bicycliques fusionnés et leurs procédés d'utilisation |
| WO2018140599A1 (fr) | 2017-01-26 | 2018-08-02 | Araxes Pharma Llc | Composés à base de benzothiophène et de benzothiazole et leurs procédés d'utilisation |
| US10736897B2 (en) | 2017-05-25 | 2020-08-11 | Araxes Pharma Llc | Compounds and methods of use thereof for treatment of cancer |
| BR112019024674A2 (pt) | 2017-05-25 | 2020-06-16 | Araxes Pharma Llc | Inibidores covalentes da kras |
| WO2018218069A1 (fr) | 2017-05-25 | 2018-11-29 | Araxes Pharma Llc | Dérivés de quinazoline utilisés en tant que modulateurs de kras, hras ou nras mutants |
| JP2020534336A (ja) * | 2017-09-20 | 2020-11-26 | ハンジョウ イノゲート ファーマ カンパニー リミテッドHangzhou Innogate Pharma Co., Ltd. | Ｉｄｏ阻害剤および／またはｉｄｏ−ｈｄａｃ二重阻害剤としての多環式化合物 |
| KR20200088308A (ko) | 2017-09-27 | 2020-07-22 | 인사이트 코포레이션 | Tam 억제제로서 유용한 피롤로트리아진 유도체의 염 |
| CN108191871B (zh) * | 2018-01-02 | 2020-02-18 | 成都倍特药业有限公司 | 新型布鲁顿酪氨酸激酶抑制剂及其制备方法和应用 |
| JP2021529765A (ja) | 2018-06-29 | 2021-11-04 | インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ | Ａｘｌ／ｍｅｒ阻害剤の製剤 |
| CN112424203B (zh) * | 2018-07-20 | 2022-07-26 | 正大天晴药业集团股份有限公司 | 布鲁顿酪氨酸激酶抑制剂 |
| CN111454268B (zh) * | 2019-01-18 | 2023-09-08 | 明慧医药（上海）有限公司 | 作为布鲁顿酪氨酸激酶抑制剂的环状分子 |
| EA202192575A1 (ru) | 2019-03-21 | 2022-01-14 | Онксео | Соединения dbait в сочетании с ингибиторами киназ для лечения рака |
| CN110724143B (zh) * | 2019-10-09 | 2021-03-23 | 清华大学 | 一种靶向btk蛋白降解化合物的制备及其在治疗自身免疫系统疾病与肿瘤中的应用 |
| US20220401436A1 (en) | 2019-11-08 | 2022-12-22 | INSERM (Institute National de la Santé et de la Recherche Médicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
| JP2023510604A (ja) | 2020-01-20 | 2023-03-14 | ジェンザイム・コーポレーション | 再発型多発性硬化症（ｒｍｓ）用の治療用チロシンキナーゼ阻害剤 |
| WO2021148581A1 (fr) | 2020-01-22 | 2021-07-29 | Onxeo | Nouvelle molécule dbait et son utilisation |
| WO2021180107A1 (fr) * | 2020-03-12 | 2021-09-16 | Fochon Pharmaceuticals, Ltd. | Composés utiles en tant qu'inhibiteurs de kinase |
| CN111471048B (zh) * | 2020-04-30 | 2021-06-15 | 成都海博为药业有限公司 | 一种具有含氮桥环、螺环或并环结构的化合物及其用途 |
| CN113527300B (zh) * | 2020-06-04 | 2023-02-03 | 广州百霆医药科技有限公司 | 布鲁顿酪氨酸蛋白激酶抑制剂 |
| CN114075190A (zh) * | 2020-08-20 | 2022-02-22 | 北京诺诚健华医药科技有限公司 | 杂环类btk抑制剂 |
| CN114634512B (zh) * | 2020-12-16 | 2023-11-14 | 江苏恒瑞医药股份有限公司 | 作为布鲁顿酪氨酸激酶抑制剂的化合物、其制备方法和医药应用 |
| WO2022140246A1 (fr) | 2020-12-21 | 2022-06-30 | Hangzhou Jijing Pharmaceutical Technology Limited | Procédés et composés destinés à l'autophagie ciblée |
| CN113512034B (zh) * | 2021-03-17 | 2022-08-09 | 湖南师范大学 | 多信号荧光探针的合成及其同时区分Cys、SO2、GSH和Hcy的应用 |
| CN117377675A (zh) * | 2021-06-01 | 2024-01-09 | 正大天晴药业集团股份有限公司 | 含有并环或螺环的布鲁顿酪氨酸激酶降解剂 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69416518T2 (de) * | 1993-07-23 | 1999-07-01 | Merrell Pharma Inc | Neue 9-n-bicyclische nucleosidverbindungen nützlich als selektive inhibitoren von proinflammatorische cytokinen |
| BR9913887A (pt) | 1998-09-18 | 2001-10-23 | Basf Ag | Composto, e, métodos de inibir a atividade de proteìna quinase, de tratar um paciente que tenha uma condição que seja mediada pela atividade da proteìna quinase e de diminuir a fertilidade em um paciente |
| US6921763B2 (en) | 1999-09-17 | 2005-07-26 | Abbott Laboratories | Pyrazolopyrimidines as therapeutic agents |
| NZ517758A (en) * | 1999-09-17 | 2004-06-25 | Abbott Gmbh & Co | Pyrazolopyrimidines useful as therapeutic agents |
| WO2001072751A1 (fr) * | 2000-03-29 | 2001-10-04 | Knoll Gesellschaft Mit Beschraenkter Haftung | Pyrrolopyrimidines utilisees comme inhibiteurs de tyrosine kinases |
| AU2004282219C1 (en) | 2003-10-15 | 2009-12-17 | Osi Pharmaceuticals, Inc. | Imidazo [1, 5 - a] pyrazine tyrosine kinase inhibitors |
| EP2081435B1 (fr) * | 2006-09-22 | 2016-05-04 | Pharmacyclics LLC | Inhibiteurs de la tyrosine kinase de bruton |
| JP5347202B2 (ja) * | 2007-03-28 | 2013-11-20 | ファーマサイクリックス，インク． | ブルトンチロシンキナーゼインヒビター |
| CN102159214A (zh) * | 2008-07-16 | 2011-08-17 | 药品循环公司 | 用于实体肿瘤的治疗的布鲁顿酪氨酸激酶的抑制剂 |
| US7741330B1 (en) * | 2009-10-12 | 2010-06-22 | Pharmacyclics, Inc. | Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase |
| JP5985658B2 (ja) * | 2012-01-31 | 2016-09-06 | ナンジン アルゲン ファルマ カンパニー リミテッドＮａｎｊｉｎｇ Ａｌｌｇｅｎ Ｐｈａｒｍａ Ｃｏ． Ｌｔｄ． | ブルトンチロシンキナーゼ阻害薬としての環状分子 |
-
2015
- 2015-02-02 MX MX2016009403A patent/MX2016009403A/es unknown
- 2015-02-02 JP JP2016547533A patent/JP6162904B2/ja not_active Expired - Fee Related
- 2015-02-02 US US15/112,536 patent/US9840509B2/en not_active Expired - Fee Related
- 2015-02-02 EP EP15723047.5A patent/EP3102579B1/fr active Active
- 2015-02-02 CA CA2934989A patent/CA2934989C/fr not_active Expired - Fee Related
- 2015-02-02 EA EA201691302A patent/EA201691302A1/ru unknown
- 2015-02-02 WO PCT/IN2015/000063 patent/WO2015132799A2/fr active Application Filing
- 2015-02-02 TW TW104103409A patent/TWI542588B/zh not_active IP Right Cessation
- 2015-02-02 SG SG11201605417QA patent/SG11201605417QA/en unknown
- 2015-02-02 AP AP2016009297A patent/AP2016009297A0/en unknown
- 2015-02-02 NZ NZ721617A patent/NZ721617A/en not_active IP Right Cessation
- 2015-02-02 AU AU2015225745A patent/AU2015225745B2/en not_active Ceased
- 2015-02-02 CN CN201580004948.7A patent/CN105916859A/zh active Pending
- 2015-02-02 BR BR112016016844A patent/BR112016016844A2/pt not_active Application Discontinuation
-
2016
- 2016-07-03 IL IL246564A patent/IL246564A/en not_active IP Right Cessation
- 2016-07-20 PH PH12016501440A patent/PH12016501440A1/en unknown
- 2016-09-28 HK HK16111345.1A patent/HK1223100A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2017504627A (ja) | 2017-02-09 |
| TWI542588B (zh) | 2016-07-21 |
| EA201691302A1 (ru) | 2017-03-31 |
| JP6162904B2 (ja) | 2017-07-12 |
| EP3102579A2 (fr) | 2016-12-14 |
| CA2934989C (fr) | 2017-08-08 |
| PH12016501440A1 (en) | 2016-08-22 |
| IL246564A (en) | 2016-11-30 |
| NZ721617A (en) | 2018-01-26 |
| AU2015225745A1 (en) | 2016-07-07 |
| CN105916859A (zh) | 2016-08-31 |
| TW201542549A (zh) | 2015-11-16 |
| US20160376277A1 (en) | 2016-12-29 |
| HK1223100A1 (zh) | 2017-07-21 |
| MX2016009403A (es) | 2016-09-16 |
| BR112016016844A2 (pt) | 2017-08-08 |
| WO2015132799A3 (fr) | 2015-11-12 |
| AP2016009297A0 (en) | 2016-06-30 |
| US9840509B2 (en) | 2017-12-12 |
| WO2015132799A2 (fr) | 2015-09-11 |
| EP3102579B1 (fr) | 2019-04-10 |
| CA2934989A1 (fr) | 2015-09-11 |
| AU2015225745B2 (en) | 2017-04-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1223100A1 (zh) | 雜環化合物 | |
| IL247018A0 (en) | Heterocyclic compound | |
| AP2017009836A0 (en) | Aminopyridyloxypyrazole compounds | |
| IL248991B (en) | Converted dihydroisoquinolinone compounds | |
| GB201411418D0 (en) | Compounds | |
| GB201410430D0 (en) | Compounds | |
| GB201402431D0 (en) | Compounds | |
| IL285105A (en) | Heterocyclic compound | |
| GB201404987D0 (en) | Compounds | |
| GB201406591D0 (en) | Compounds | |
| GB201406956D0 (en) | Compounds | |
| AP2017009778A0 (en) | Azetidinyloxyphenylpyrrolidine compounds | |
| GB201412660D0 (en) | Compounds | |
| PL3159335T3 (pl) | Nowy związek heterocykliczny | |
| GB201416351D0 (en) | Heterocyclic derivatives | |
| GB201407695D0 (en) | Compounds | |
| GB201405361D0 (en) | Compounds | |
| GB201411402D0 (en) | Compounds | |
| GB201411119D0 (en) | Compounds | |
| GB201410604D0 (en) | Compounds | |
| GB201410017D0 (en) | Compounds | |
| GB201407697D0 (en) | Compounds | |
| GB201407696D0 (en) | Compounds | |
| GB201403809D0 (en) | Compounds | |
| GB201401784D0 (en) | Compounds |